Raptech Pharma Technologies Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 50.00 K
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 129.22%
- Profit Growth 88.59%
- Ebitda 84.01%
- Net Worth 119.66%
- Total Assets 40.45%
About Raptech Pharma Technologies
Raptech Pharma Technologies Private Limited (RPTPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 April 2018 (Six years and nine months 28 days old ). Its registered office is in Raigarh, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 50.00 K , as per Ministry of Corporate Affairs (MCA) records.
Arati Singh and Amrendar Singh serve as directors at the Company.
Company Details
-
Location
Raigarh, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U73100MH2018PTC307538
-
Company No.
307538
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Apr 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Raptech Pharma Technologies?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arati Singh
|
Director | 06-Jun-2024 | Current |
|
Amrendar Singh
|
Director | 05-Apr-2018 | Current |
Financial Performance of Raptech Pharma Technologies.
Raptech Pharma Technologies Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 129.22% increase. The company also saw a substantial improvement in profitability, with a 88.59% increase in profit. The company's net worth Soared by an impressive increase of 119.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Raptech Pharma Technologies?
In 2020, Raptech Pharma Technologies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Aps Pharmatechnologies Private LimitedArati Singh is a mutual person
-
Raptech Laboratories Private Limited
Amrendar Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Raptech Pharma Technologies?
Unlock and access historical data on people associated with Raptech Pharma Technologies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Raptech Pharma Technologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Raptech Pharma Technologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
